Genedata Provides R&D Knowledge Management System to Support Bayer Schering Pharma’s Biologics Research
Data management and analysis system supports key informatics tasks for biologics discovery at Bayer Schering Pharma centers across Europe and the US
January 5, 2010
Basel, Switzerland and Lexington, MA, USA
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, and Bayer Schering Pharma AG, one of the world’s leading global specialty pharmaceutical companies, today announced a multi-year collaboration for the development and implementation of the Biologics Data Platform (BDP). BDP will support biologics data management and analysis at Bayer Schering Pharma R&D sites worldwide, which are developing novel protein-based therapeutics for diseases such as cancer, hemophilia, and multiple sclerosis.
“The Biologics Data Platform is an important system for our daily operations as it makes the highly interconnected biologics R&D processes more efficient,” explained Dr. Heiner Apeler, director of Molecular and Antibody Biology at Bayer Schering Pharma. “The BDP supports our scientists in a complex, multi-site environment by providing all the necessary information and tools to streamline the biologics lead generation and optimization process. At the same time, the BDP will provide a complete historical record of our therapeutic proteins, which will be important for downstream biologics development.”
Comprehensive Platform Supports Complete Biologics R&D
The BDP provides a shared data storage and data exchange platform to synchronize Bayer Schering Pharma’s activities starting with biologics screening all the way through to production. Developed for both antibody-based and other protein therapeutics, the platform supports key informatics tasks from library generation and laboratory logistics to biologics registration and analytics. The platform directly interacts with laboratory equipment such as screening robots and integrates into Bayer Schering Pharma’s existing IT infrastructure.
“We are excited about the collaboration with Bayer Schering Pharma in the area of biologics R&D,” said Dr. Othmar Pfannes, CEO of Genedata. “Genedata has broad experience with biological sequence management, screening data analysis and other complex laboratory processes. As the market for protein therapeutics expands, the demand for new software to efficiently support the biologics R&D process is increasing and Genedata is well-positioned to provide cutting-edge solutions to our customers.”
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
The Biologics Data Platform makes the highly interconnected biologics R&D processes more efficient
Dr. Heiner Apeler
Director of Molecular and Antibody Biology